'Acute on chronic' effect of depot leuprolide in patients with stage D2 cancer of prostate.

R. Sharifi, M. Soloway, M. Clayton, A. Mounzer, M. Strub, P. Siami, M. Lee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

During a phase III open study of depot leuprolide for stage D2 cancer of the prostate, we studied the effect of depot leuprolide on chronic leuprolide users. To determine whether there was a transient elevation of testosterone or luteinizing hormone (LH) 4-24 h and 3-5 days following the monthly injections, we monitored the changes of testosterone and LH before injection and 24 h post-injection in 10 patients who have been under depot leuprolide Rx for 24-36 weeks, and in 35 patients before injection and 3-5 days post-injection who have received depot leuprolide for 8-24 weeks prior to monitoring. Comparison of the data between pre-injection within 24 h and 3-5 days post-injection showed no significant changes of testosterone and LH values between these levels for either testosterone (P = 0.31) or LH (P = 0.45). We therefore conclude that there was no 'acute on chronic' effect of depot formulation in chronic users of depot leuprolide.

Original languageEnglish
Pages (from-to)29-31
Number of pages3
JournalAnti-Cancer Drugs
Volume1
Issue number1
StatePublished - Oct 1 1990
Externally publishedYes

Fingerprint

Leuprolide
Prostatic Neoplasms
Injections
Luteinizing Hormone
Testosterone

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Sharifi, R., Soloway, M., Clayton, M., Mounzer, A., Strub, M., Siami, P., & Lee, M. (1990). 'Acute on chronic' effect of depot leuprolide in patients with stage D2 cancer of prostate. Anti-Cancer Drugs, 1(1), 29-31.

'Acute on chronic' effect of depot leuprolide in patients with stage D2 cancer of prostate. / Sharifi, R.; Soloway, M.; Clayton, M.; Mounzer, A.; Strub, M.; Siami, P.; Lee, M.

In: Anti-Cancer Drugs, Vol. 1, No. 1, 01.10.1990, p. 29-31.

Research output: Contribution to journalArticle

Sharifi, R, Soloway, M, Clayton, M, Mounzer, A, Strub, M, Siami, P & Lee, M 1990, ''Acute on chronic' effect of depot leuprolide in patients with stage D2 cancer of prostate.', Anti-Cancer Drugs, vol. 1, no. 1, pp. 29-31.
Sharifi R, Soloway M, Clayton M, Mounzer A, Strub M, Siami P et al. 'Acute on chronic' effect of depot leuprolide in patients with stage D2 cancer of prostate. Anti-Cancer Drugs. 1990 Oct 1;1(1):29-31.
Sharifi, R. ; Soloway, M. ; Clayton, M. ; Mounzer, A. ; Strub, M. ; Siami, P. ; Lee, M. / 'Acute on chronic' effect of depot leuprolide in patients with stage D2 cancer of prostate. In: Anti-Cancer Drugs. 1990 ; Vol. 1, No. 1. pp. 29-31.
@article{fba12473662340c6b4058d3bde8dc969,
title = "'Acute on chronic' effect of depot leuprolide in patients with stage D2 cancer of prostate.",
abstract = "During a phase III open study of depot leuprolide for stage D2 cancer of the prostate, we studied the effect of depot leuprolide on chronic leuprolide users. To determine whether there was a transient elevation of testosterone or luteinizing hormone (LH) 4-24 h and 3-5 days following the monthly injections, we monitored the changes of testosterone and LH before injection and 24 h post-injection in 10 patients who have been under depot leuprolide Rx for 24-36 weeks, and in 35 patients before injection and 3-5 days post-injection who have received depot leuprolide for 8-24 weeks prior to monitoring. Comparison of the data between pre-injection within 24 h and 3-5 days post-injection showed no significant changes of testosterone and LH values between these levels for either testosterone (P = 0.31) or LH (P = 0.45). We therefore conclude that there was no 'acute on chronic' effect of depot formulation in chronic users of depot leuprolide.",
author = "R. Sharifi and M. Soloway and M. Clayton and A. Mounzer and M. Strub and P. Siami and M. Lee",
year = "1990",
month = "10",
day = "1",
language = "English",
volume = "1",
pages = "29--31",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - 'Acute on chronic' effect of depot leuprolide in patients with stage D2 cancer of prostate.

AU - Sharifi, R.

AU - Soloway, M.

AU - Clayton, M.

AU - Mounzer, A.

AU - Strub, M.

AU - Siami, P.

AU - Lee, M.

PY - 1990/10/1

Y1 - 1990/10/1

N2 - During a phase III open study of depot leuprolide for stage D2 cancer of the prostate, we studied the effect of depot leuprolide on chronic leuprolide users. To determine whether there was a transient elevation of testosterone or luteinizing hormone (LH) 4-24 h and 3-5 days following the monthly injections, we monitored the changes of testosterone and LH before injection and 24 h post-injection in 10 patients who have been under depot leuprolide Rx for 24-36 weeks, and in 35 patients before injection and 3-5 days post-injection who have received depot leuprolide for 8-24 weeks prior to monitoring. Comparison of the data between pre-injection within 24 h and 3-5 days post-injection showed no significant changes of testosterone and LH values between these levels for either testosterone (P = 0.31) or LH (P = 0.45). We therefore conclude that there was no 'acute on chronic' effect of depot formulation in chronic users of depot leuprolide.

AB - During a phase III open study of depot leuprolide for stage D2 cancer of the prostate, we studied the effect of depot leuprolide on chronic leuprolide users. To determine whether there was a transient elevation of testosterone or luteinizing hormone (LH) 4-24 h and 3-5 days following the monthly injections, we monitored the changes of testosterone and LH before injection and 24 h post-injection in 10 patients who have been under depot leuprolide Rx for 24-36 weeks, and in 35 patients before injection and 3-5 days post-injection who have received depot leuprolide for 8-24 weeks prior to monitoring. Comparison of the data between pre-injection within 24 h and 3-5 days post-injection showed no significant changes of testosterone and LH values between these levels for either testosterone (P = 0.31) or LH (P = 0.45). We therefore conclude that there was no 'acute on chronic' effect of depot formulation in chronic users of depot leuprolide.

UR - http://www.scopus.com/inward/record.url?scp=0025502489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025502489&partnerID=8YFLogxK

M3 - Article

C2 - 2131032

AN - SCOPUS:0025502489

VL - 1

SP - 29

EP - 31

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 1

ER -